CKR-051 is under clinical development by CK Regeon and currently in Phase I for Wounds. According to GlobalData, Phase I drugs for Wounds does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CKR-051 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CKR-051 overview
CKR-051 is under development for the treatment of hair loss, diabetic foot ulcer and wounds. It is administered by the transdermal route. The drug candidate acts by targeting CXXC-type zinc finger protein 5 (CXXC5).
CK Regeon overview
CK Biotech Inc., is a biotechnology company that discover and develop First-In-?Class drugs with clear MOA. The company is headquartered Republic of Korea (South Korea).
For a complete picture of CKR-051’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
